Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Overview & updates on the MOMENTUM trial comparing momelotinib and danazol in myelofibrosis

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, describes the structure, aims, and results of the MOMENTUM study (NCT04173494), which aims to compare the efficacy of momelotinib to danazol in treating myelofibrosis (MF), highlighting the place of momelotinib in the treatment algorithm of MF. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

AOP: Consultancy; Promedior: Research Funding; Genotech: Research Funding; Samus: Consultancy, Research Funding; AbbVie: Research Funding; LaJolla Pharmaceutical: Consultancy; Sierra Oncology: Consultancy, Research Funding; Constellation Pharmaceuticals, Inc., a MorphoSys Company: Consultancy, Research Funding; CTI: Research Funding; Roche: Consultancy; Celgene: Research Funding; Incyte: Consultancy, Research Funding; Blueprint: Consultancy; Bristol Myers Squibb: Consultancy; Novartis: Consultancy; Geron: Consultancy; Gilead: Research Funding; Imago: Research Funding.